Autoantibody status and association with HRCT lung abnormalities
| RF and ACPA fine specificities | All patients | HRCT airway abnormalities | HRCT parenchymal abnormalities | ||||
|---|---|---|---|---|---|---|---|
| No | Yes | P value | No | Yes | P value (adjusted p value) | ||
| Number | 106 | 38 | 68 | 48 | 58 | ||
| Any RF | 73 (69.5) | 27 (71.1) | 46 (68.7) | 0.80 | 29 (61.7) | 44 (75.9) | 0.12 |
| RF (IgM) | 73 (69.5) | 27 (71.1) | 46 (68.7) | 0.80 | 29 (61.7) | 44 (75.9) | 0.12 |
| RF (IgA) | 52 (49.5) | 18 (47.4) | 34 (50.7) | 0.74 | 17 (36.2) | 35(60.3) | 0.014 (0.25) |
| Any anti-CCP2 | 72 (68.6) | 25 (65.8) | 47 (70.1) | 0.64 | 27 (57.4) | 45 (77.6) | 0.027 (0.49) |
| CCP2 (IgG) | 71 (67.6) | 25 (65.8) | 46 (68.7) | 0.76 | 27 (57.4) | 44 (75.9) | 0.045 (0.81) |
| CCP2 (IgA) | 32 (30.5) | 9 (23.7) | 23 (34.3) | 0.26 | 12 (25.5) | 20 (34.5) | 0.32 |
| Any RF and anti-CCP2-negative | 24 (22.9) | 8 (21.1) | 16 (23.9) | 0.74 | 16 (34.0) | 8 (13.8) | 0.014 (0.25) |
| Anti-CEP-1 | 41 (38.7) | 12 (31.6) | 29 (42.6) | 0.26 | 18 (37.5) | 23 (39.7) | 0.82 |
| Anti-CCP-1 | 48 (45.3) | 17 (44.7) | 31 (45.6) | 0.93 | 19 (39.6) | 29 (50.0) | 0.28 |
| Any anti-cit vimentin | 64 (61.0) | 21 (55.3) | 43 (64.2) | 0.37 | 26 (55.3) | 38 (65.5) | 0.29 |
| Vim 2-17 | 44 (42.7) | 14 (38.9) | 30 (44.8) | 0.57 | 17 (36.2) | 27 (48.2) | 0.22 |
| Vim 60-75 | 57 (53.8) | 17 (44.7) | 40 (58.8) | 0.16 | 23 (47.9) | 34 (58.6) | 0.27 |
| Any anti-cit fibrinogen | 77 (72.6) | 28 (73.7) | 49 (72.1) | 0.86 | 30 (62.5) | 47 (81.0) | 0.033 (0.59) |
| Fibα 36-50 | 28 (26.4) | 12 (31.6) | 16 (23.5) | 0.37 | 11 (22.9) | 17 (29.3) | 0.46 |
| Fibα 563-583 | 50 (47.2) | 19 (50.0) | 31 (45.6) | 0.66 | 19 (39.6) | 31 (53.4) | 0.16 |
| Fibα 580-600 | 20 (18.9) | 6 (15.8) | 14 (20.6) | 0.55 | 9 (18.8) | 11 (19.0) | 0.98 |
| Fibα 621-635 | 38 (35.8) | 11 (28.9) | 27 (39.7) | 0.27 | 14 (29.2) | 24 (41.4) | 0.19 |
| Fibβ 36-52 | 48 (45.3) | 14 (36.8) | 34 (50.0) | 0.19 | 19 (39.6) | 29 (50.0) | 0.28 |
| Fibβ 60-74 | 57 (53.8) | 21 (55.3) | 36 (52.9) | 0.82 | 23 (47.9) | 34 (58.6) | 0.27 |
| Number of ACPA fine specificities | |||||||
| 0 | 24 (22.6) | 9 (23.7) | 15 (22.1) | 0.43 | 15 (31.3) | 9 (15.5) | 0.12 |
| 1–5 | 43 (40.6) | 18 (47.4) | 25 (36.8) | 19 (39.6) | 24 (41.4) | ||
| >5 | 39 (36.8) | 11 (28.9) | 28 (41.2) | 14 (29.2) | 25 (43.1) | ||
| 0–1 | 37 (35.2) | 13 (35.1) | 24 (35.3) | 0.99 | 19 (39.6) | 18 (31.6) | 0.39 |
| >1 | 68 (64.8) | 24 (64.9) | 44 (64.7) | 29 (60.4) | 39 (98.4) | ||
The values indicated in the table represent the numbers and those in parenthesis indicate the % of reactivity (columnwise) in each category. The p values were obtained by χ² test that was used to compare categorical variables. The bolded values represent statistically significant p values (p<0.05). The p values in parentheses represent the adjusted values for multiple test (Bonferroni).
ACPA, anticitrullinated protein/peptide antibodies; CCP, cyclic citrullinated peptide; CEP, citrullinated enolase peptide; cit, citrullinated/citrullination; Fib, fibrinogen; HRCT, high-resolution CT; RF, rheumatoid factor; Vim, vimentin.